Compare Church & Dwight Co., Inc. (CHD) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Church & Dwight Co., Inc. vs Revvity Inc — how do they compare? Church & Dwight Co., Inc. trades at $102.84 (market cap $24.38B), while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Church & Dwight Co., Inc. is the larger of the two by market cap, and Church & Dwight Co., Inc. pays the higher dividend (1.2%). Which is the better fit depends on your goals.
| CHD | RVTY | |
|---|---|---|
Market Cap | $24.38B | $12.91B |
Sector | Consumer Staples | Technology |
52-Week High | $105.26 | $117.75 |
52-Week Low | $81.60 | $82.26 |
Enterprise Value | $26.38B | $15.23B |
Dividend Yield | 1.2% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Church & Dwight (CHD) trades at $101.56, down 1.68% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results with 5.8% organic sales growth, beating expectations, and raised full-year guidance. Valuation ratios are elevated with a P/E of 32.94, while profitability remains solid with a net income margin of 11.96%.
Outlook is positive driven by volume growth and market share gains, but risks include high valuation and competitive pressures. Analysts are bullish with a $103.57 consensus target, offering modest upside from current levels amid steady cash flows and dividend payments.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
